A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00153868
First received: September 8, 2005
Last updated: August 1, 2013
Last verified: July 2013

September 8, 2005
August 1, 2013
October 2003
September 2013   (final data collection date for primary outcome measure)
A secure web-based assessment of cancer-related symptoms (LCSS), functional status (SF-36), and quality of life (FACT-An and PFS) will be obtained every 2 weeks (weeks 3, 5, 7, 9, 11, and 13). [ Time Frame: every 2 weeks (weeks 3, 5, 7, 9, 11, and 13) ] [ Designated as safety issue: No ]
A secure web-based assessment of cancer-related symptoms (LCSS), functional status (SF-36), and quality of life (FACT-An and PFS) will be obtained every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).
Complete list of historical versions of study NCT00153868 on ClinicalTrials.gov Archive Site
  • A blood sample will be obtained to evaluate hemoglobin concentrations every 2 weeks (weeks 3, 5, 7, 9, 11, and 13). [ Time Frame: every 2 weeks (weeks 3, 5, 7, 9, 11, and 13) ] [ Designated as safety issue: No ]
  • A blood sample will be obtained to evaluate plasma cytokines every 4 weeks (weeks 5, 9, and 13). [ Time Frame: every 4 weeks (weeks 5, 9, and 13) ] [ Designated as safety issue: No ]
  • A blood sample will be obtained to evaluate hemoglobin concentrations every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).
  • A blood sample will be obtained to evaluate plasma cytokines every 4 weeks (weeks 5, 9, and 13).
Not Provided
Not Provided
 
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
Pilot Web-based Study of Functional Status, Symptom Palliation and Quality of Life Benefits Associated With Darbepoetin Alfa (Aranesp®) Administration in Anemic Patients With Cancer.

This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data capture will be evaluated.

Anemia associated with lung cancer and chemotherapy is an important factor effecting patient symptoms, functional status, and overall quality of life (Groopman and Itri 1999; Langer, Choy et al. 2002). Darbepoetin alfa (Aranesp®) has demonstrated a significant effect upon ameliorating chemotherapy-induced anemia in lung cancer (Vansteenkiste, Pirker et al. 2002; Vansteenkiste, Poulsen et al. 2002). This trial is designed to evaluate the association between the treatment of anemia with darbepoetin alfa and direct electronic capture of clinical benefits in cancer-related symptoms, functional status and overall quality of life. This trial uses a secure web-based design to capture the patient-associated symptoms, functional status and quality of life. This novel secure web-based system was selected to improve the efficiency and quality of clinical data capture. If our hypothesis is correct, treatment with darbepoetin alfa will be associated with improved palliation of cancer-related symptoms, improved functional status, and result in overall benefits to the patient's health-related quality of life. The development of a web-based system to directly capture patient-related symptoms, functional status and quality of life will permit us in the future to conduct a national or international trial addressing the effects of darbepoetin alfa on these factors. If our hypothesis is incorrect, it may be that these parameters are not affected by the correction of anemia with darbepoetin alfa or the measures are not sensitive enough to detect these differences. A notable finding would be a clearly defined improvement in symptom palliation, functional status, and quality of life associated with darbepoetin alfa therapy.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Anemia
  • Cancer
Drug: darbepoetin alfa
The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
Other Name: aranesp
  • Active Comparator: 1
    Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
    Intervention: Drug: darbepoetin alfa
  • Active Comparator: 2
    darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
    Intervention: Drug: darbepoetin alfa
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
103
September 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmation of non-myeloid cancer (myeloproliferative disorders will be excluded).
  • Hemoglobin concentration ≤ 11.0 g/dL.
  • Age ≥ 18 years.
  • Karnofsky performance status ≥ 60%.
  • Anemia predominantly due to cancer or chemotherapy.
  • Serum creatinine concentration ≤ 2.0 mg/dL.
  • Total serum bilirubin ≤ 1.5 times the upper limit of normal.
  • Nutritional status adequate to provide vitamin B12 and folate within the normal limits.
  • Capacity to complete the web-based functional status, symptom and quality of life assessments.
  • Ability to give informed consent.

Exclusion Criteria:

  • Untreated symptomatic primary or metastatic cancer involving the central nervous system.
  • History of clinically significant iron deficiency.
  • Greater than two red blood cell transfusions within 2 weeks of registration or any red blood cell transfusion within 7 days of registration.
  • Received epoetin alfa or darbepoetin alfa therapy within 3 weeks prior to randomization.
  • History of a seizure disorder.
  • Unstable angina, congestive heart failure (New York Heart Association > class II or known ejection fraction < 40%) or uncontrolled cardiac arrhythmias.
  • Uncontrolled hypertension defined as a diastolic blood pressure > 100 mmHg.
  • Clinical evidence of active infection or inflammatory diseases such as rheumatoid arthritis. Subjects with active rheumatoid arthritis are excluded.
  • Known positive test for human immunodeficiency virus infection.
  • Known primary hematological disorder which could cause anemia such as sickle cell anemia.
  • Pregnant or breast-feeding.
  • Not using adequate contraception if of childbearing potential.
  • Known hypersensitivity to any recombinant mammalian-derived product.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00153868
D-0341
Yes
Dartmouth-Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center
Amgen
Principal Investigator: James R Rigas, MD Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP